Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 0.44 |
| ▸ | CTRC | Q99895 | 2/20 | 0.42 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CDH1 | P12830 | 1/20 | 0.38 |
| ▸ | APC | P25054 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409583 | 0.82 | LDHA (0.44) | LDHACTRCP4HA1P4HTMMAPT | |
| SCHEMBL3072242 | 0.80 | LDHA (0.42) | LDHACTRCP4HA1P4HTMMAPT | |
| SCHEMBL22395356 | 0.79 | RXRA (0.47) | LDHACTRCKMO | |
| SCHEMBL3068918 | 0.78 | CYP2C9 (0.52) | LDHACTRCP4HA1P4HTMMAPT | |
| SCHEMBL18496631 | 0.78 | RXRA (0.55) | CTRCCDH1APCCTNNB1TCF7L2 | |
| SCHEMBL29727618 | 0.78 | RXRA (0.55) | CTRCCDH1APCCTNNB1TCF7L2 | |
| SCHEMBL2949623 | 0.78 | LDHA (0.61) | LDHACTRCP4HA1P4HTMNPC1 | |
| SCHEMBL3661059 | 0.75 | NPC1 (0.41) | LDHACTRCP4HA1P4HTMMAPT | |
| SCHEMBL16684293 | 0.73 | NPC1 (0.42) | LDHAP4HA1P4HTMNPC1RAB9A | |
| SCHEMBL31486221 | 0.73 | LDHA (0.53) | LDHAP4HA1P4HTMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225213-B1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-29 | — | — | EP | disclosed |
| EP-2607356-B1 | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2607356-A1 | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-8440708-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2011-10-06 | — | — | US | disclosed |
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | disclosed |
| CN-101903359-A | Triazole-substituted arylamide derivatives and their use as P2X3And/or P2X2/3Use of purinergic receptor antagonists | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| EP-2225213-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| WO-2009077366-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | LDHA 4769/4885CTRC 2408/4885P4HA1 1125/4885 |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | LDHA 4769/4885CTRC 2408/4885P4HA1 1125/4885 |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | P2RX3, P2RX2, P2RX7 | LDHA 4821/4885CTRC 2972/4885P4HA1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.